Please assess the completion status of the following clinical trial:

Trial Title: A Study of PRT-201 Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-1)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age of at least 18 years.~2. Life expectancy of at least 6 months.~3. Diagnosis of Chronic Kidney Disease (CKD).~4. Planned creation of a new radiocephalic arteriovenous fistula (AVF)-revision of an existing AVF is not eligible.~5. Ability to understand and comply with the requirements of the entire study and to communicate with the study team.~6. Written informed consent using a document that has been approved by the Institutional Review Board (IRB).~7. If female and of childbearing potential (premenopausal and not surgically sterile) must have a negative serum pregnancy test at the screening visit (Visit 1) and be willing to use contraception from the time of the screening visit to 2 weeks following study drug administration. Acceptable methods of birth control include abstinence, barrier methods, hormones, or intra uterine device.~Exclusion Criteria:~1. Malignancy or treatment for malignancy within the previous 12 months with the exception of the following cancers if they have been resected: localized basal cell or squamous cell skin cancer, or any cancer in situ.~2. Presence of any significant medical condition that might significantly confound the collection of safety and efficacy data in this study.~3. Previous treatment with PRT 201.~4. Treatment with any investigational drug within the previous 30 days or investigational antibody therapy within the previous 90 days prior to signing informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- PRT-201 (Type: ACTIVE_COMPARATOR): PRT-201 administered at the time of radiocephalic fistula creation
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered at the time of radiocephalic fistula creation. The placebo is identical in appearance and composition to PRT-201 but lacks the active ingredient.

Based on this trial design, predict the completion outcome and termination type (if applicable).